# US 11,433,122 B1 · NK-lysin peptide compositions and methods for their use as antimicrobial/antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,122 B1
- Document ID: US11433122B1
- Status: Granted
- Kind: B1
- Application number: 17/574,101
- Filed: 2022-01-12
- Published: 2022-09-29
- Granted: 2022-09-06
- Earliest claimed: 2021-03-26
- Assignees: King Abdulaziz University
- Applicants: King Abdulaziz University
- Inventors: Maged Mostafa Mahmoud; Haitham A. Yacoub; Ahmed M. Al-Hejin; Turki Abujaml; Sherif Abd-Elmaksoud
- Web page: https://patentgrep.com/patent/US11433122B1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 33/38: Silver; Compounds thereof
- A61K 38/1709: {from mammals}
- A61K 38/2013: {IL-2}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Natural killer (NK)-lysin peptides from chicken, bovine and human species are used as an antimicrobial or antiviral agent alone or in combination with other agents. A pharmaceutical composition comprising NK-lysin peptides was effective against Rotavirus and various gram-negative and gram-positive bacteria that were tested. Combinations of NK-lysin peptides plus silver nanoparticles or IL-2 were also effective against Salmonella typhimurium. Treatment with the NK-lysin peptides repressed β-lactam-resistance genes (CTX-M-1, CTX-M-8 and CTX-M-9) in bacterial species tested and thus can be used to augment treatment with β-lactams and increase bacterial sensitivity to this important class of antibiotics.

## Claims

### Claim 1

A method for treating a rotaviral infection in a subject in need thereof, comprising the step of
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an NK-lysin peptide, wherein the NK-lysin peptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NK-lysin peptide has the amino acid sequence of SEQ ID NO:2.